(Q42541808)

2 November 2017

title

Summary of clinical trials with zafirlukast (English)

1 reference

2 November 2017

1 reference

Calhoun WJ

1

1 reference

2 November 2017

language of work or name

English

0 references

publication date

1 June 1998

1 reference

American Journal of Respiratory and Critical Care Medicine

2 November 2017

published in

1 reference

2 November 2017

volume

157

1 reference

2 November 2017

issue

6 Pt 1

1 reference

2 November 2017

page(s)

S238-46

1 reference

Inhibition of leukotriene D4-induced bronchoconstriction in normal subjects by the oral LTD4 receptor antagonist ICI 204,219.

2 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.6.MAR6

Inhibition of leukotriene D4-induced bronchoconstriction in subjects with asthma: a concentration-effect study of ICI 204,219.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.6.MAR6

The leukotriene-antagonist ICI-204,219 inhibits the early airway reaction to cumulative bronchial challenge with allergen in atopic asthmatics

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.6.MAR6

Role of leukotrienes in exercise-induced asthma. Inhibitory effect of ICI 204219, a potent leukotriene D4 receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.6.MAR6

The protective effect of inhaled leukotriene D4 receptor antagonist ICI 204,219 against exercise-induced asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.6.MAR6

Potent leukotriene D4 receptor antagonist ICI 204,219 given by the inhaled route inhibits the early but not the late phase of allergen-induced bronchoconstriction

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.6.MAR6

Zafirlukast for symptomatic mild-to-moderate asthma: a 13-week multicenter study. The Zafirlukast Trialists Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.6.MAR6

Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma. A randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.6.MAR6

Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. ACCOLATE Asthma Trialists Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.6.MAR6

Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.6.MAR6

10.1164/AJRCCM.157.6.MAR6

21 January 2018

Identifiers

DOI

1 reference

2 November 2017

1 reference